Insulin Lispro Protamine/Insulin Lispro

DEA Class; Rx

Common Brand Names; Humalog Mix 50/50, Humalog Mix 50/50 Kwikpen, Humalog Mix 75/25, Humalog Mix 75/25 Kwikpen

Indicated for the treatment of type 1 diabetes mellitus.

Hypersensitivity

During episodes of hypoglycemia

Hypoglycemia

Insulin resistance

Lipodystrophy

Lipohypertrophy

Local allergic reaction

Hypokalemia

Injection site reactions

Weight gain

Edema

Pruritus

Rash

Never share pen between patients even it needle is changed

Suspension for SC use, do not administer IV

Administer within 15 minutes of meals (rapid onset and peak ~1 hr)

Rapid changes in serum glucose may induce symptoms of hypoglycemia

Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions (eg, long duration of diabetes, diabetic nerve disease, use of beta-blockers or intensified diabetes control)

Caution in conditions with decreased insulin requirements (eg, diarrhea, nausea, vomiting, malabsorption, hypothyroidism, renal impairment, hepatic impairment)

Caution in conditions with increased insulin requirements (eg, fever, hyperthyroidism, trauma, infection, surgery)

Thiazolidinediones are peroxisome proliferator-activated receptor (PPAR)-gamma agonists and can cause dose-related fluid retention, particularly when used in combination with insulin; fluid retention may lead to or exacerbate heart failure, monitor for signs and symptoms of heart failure and treat accordingly and consider discontinuing thiazolidinediones

Glucose monitoring recommended for all patients with diabetes

Do not mix with other insulins

Do not administer via insulin infusion pump

Hypoglycemia may be life-threatening; increase frequency of blood glucose monitoring with changes to insulin dosage, co-administered glucose lowering medications, meal pattern, physical activity; in patients with renal or hepatic impairment; and in patients with hypoglycemia unawareness

Accidental mix-ups between insulin products can occur; instruct patients to check insulin labels before injection

Severe, life-threatening, generalized allergy, including anaphylaxis, reported; discontinue therapy, monitor, and treat if indicated

Hypokalemia may occur; may be life-threatening; monitor potassium levels in patients at risk of hypokalemia and treat if indicated

The limited available data in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes

There are no data on presence of drug in human milk, effects on breastfed infant, or on milk production

insulin lispro protamine rDNA origin/insulin lispro rDNA origin

insulin lispro protamine/insulin lispro

subcutaneous injection

• (75units/25units)/mL
• (50units/50units)/mL